P1, N=15, Active, not recruiting, Valo Therapeutics Oy | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Oct 2026

3 months ago

Enrollment closed • Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1

almost2years

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)

P1, N=15, Recruiting, Valo Therapeutics Oy | Trial completion date: Jan 2024 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Jun 2025

almost 2 years ago

Trial completion date • Trial primary completion date • Combination therapy

PD-L1 (Programmed death ligand 1)

Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1

almost3years

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)

P1, N=15, Recruiting, Valo Therapeutics Oy | Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Feb 2023

almost 3 years ago

Enrollment open • Trial initiation date • Combination therapy

PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • MAGEA3 (MAGE Family Member A3)

Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1

over3years

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)

P1, N=15, Not yet recruiting, Valo Therapeutics Oy

over 3 years ago

New P1 trial • Combination therapy

PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • MAGEA3 (MAGE Family Member A3)

Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1